Multinuclear lung MRI assessment of COVID-19 patients at 6 and 12 weeks after hospital admission
Laura C. Saunders1, Guilhem J. Collier1, Ho-Fung Chan1, Paul J. C. Hughes1, Laurie J. Smith1, Helen Marshall1, James A. Eaden1, Jody Bray1, David J. Capener1, Leanne Armstrong1, Jennifer Rodgers1, Martin Brook1, Alberto M. Biancardi1, James Watson2, Zoë Gabriel2, Madhwesha R. Rao1, Graham Norquay1, Oliver Rodgers1, Fred Wilson3, Tony Cahn3, Andy Swift1, Smitha Rajaram2, Fergus Gleeson4,5, James T. Grist5, Gary H. Mills2,6, James Meiring2, Lisa Watson2, Paul J. Collini6, Rod Lawson2, Roger Thompson1, and Jim M. Wild1
1Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom, 2Sheffield Teaching Hospitals, Sheffield, United Kingdom, 3GlaxoSmithKline, Stevenage, United Kingdom, 4Oxford NHS Foundation Trust, Oxford, United Kingdom, 5University of Oxford, Oxford, United Kingdom, 6University of Sheffield, Sheffield, United Kingdom
This work uses a multinuclear 1H and 129Xe protocol to assess pathophysiological changes in patients with COVID-19 pneumonia, without signs of interstitial lung disease, at 6 and 12 weeks after hospital admission. 1H and 129Xe protocol: ultra-short echo time, dynamic contrast enhanced lung perfusion, 129Xe lung ventilation, 129Xe diffusion weighted MRI, 129Xe 3D spectroscopic imaging. Though significant improvements in lung ventilation homogeneity (decreased low ventilation percentage and ventilation coefficient of variation), gas transfer (increased RBC:TP, decreased TP T2*) and perfusion (increased pulmonary blood volume and flow) were seen between 6 and 12 weeks, low RBC:TP ratio persisted for some patients.
This abstract and the presentation materials are available to members only;
a login is required.